 The primary purpose of this study is to determine the maximum tolerated dose MTD and recommended Phase 2 dose RP2D of H3B-6527 Part 1, and to assess the safety and tolerability of H3B-6527 as a single agent administered orally Part 2 in participants with advanced hepatocellular carcinoma HCC or Intrahepatic Cholangiocarcinoma. 